Abzena Supplies Clinical Trial Material for Angiex’s Phase I Study of AGX101, a First-in-Class TM4SF1-directed ADC

09 August 2024

Abzena Supports Angiex’s AGX101 Phase I Clinical Trial with Critical Materials

In a key collaboration, Abzena has provided essential clinical trial materials for Angiex’s AGX101 Phase I study. AGX101 is a first-in-class TM4SF1-directed antibody-drug conjugate (ADC) that specifically targets the blood vessels in tumors, making it a highly targeted approach to treating aggressive cancers. This partnership marks a significant phase in Angiex’s progress as they work toward developing precision cancer therapies.

Bio-IT World covered this milestone, focusing on how strategic partnerships like that between Angiex and Abzena are crucial to advancing innovative oncology treatments. With a focus on life sciences and biotech, Bio-IT World highlights how these types of collaborations are driving the next generation of cancer therapies, offering new possibilities for patient care.


About Angiex

Angiex Inc. is a privately held biotech startup whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology. The company is developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus or cytosol, where the site of payload action is located. This direct delivery holds the promise of enhancing the efficacy and therapeutic margin of conventional ADCs. The lead product, AGX101, has advanced through pre-clinical development and is about to begin Phase 1 clinical trials. To learn more about Angiex...